(Q35994331)

11 August 2017

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer (English)

1 reference

11 August 2017

1

Fosså SD

1 reference

11 August 2017

H. Waehre

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1379059

20 September 2022

E. Paus

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1379059

20 September 2022

language of work or name

English

0 references

publication date

1 July 1992

1 reference

PMCID

1977889

full work available at URL

11 August 2017

https://europepmc.org/articles/PMC1977889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1379059

https://europepmc.org/articles/PMC1977889?pdf=render

20 September 2022

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1379059

British Journal of Cancer

20 September 2022

published in

1 reference

11 August 2017

66

1 reference

11 August 2017

1

1 reference

11 August 2017

181-184

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1992.239

11 August 2017

0 references

cites work

The endocrinology and treatment of prostate tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Treatment of Metastatic Endocrine-Unresponsive Carcinoma of the Prostate Gland With Multiagent Chemotherapy: indicators of Response to Therapy2

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1977889

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

23 September 2018

1 reference

12 December 2020

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

1 reference

12 December 2020

Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer

1 reference

12 December 2020

Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice

1 reference

12 December 2020

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1992.239

1 reference

PMCID

1977889

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

1 reference

PMCID

1977889